Abstract

Drug development is a lengthy and costly process that proceeds through several stages from target identification to lead discovery and optimization, preclinical validation and clinical trials culminating in approval for clinical use. An important step in this process is high-throughput screening (HTS) of small compound libraries for lead identification. Currently, the majority of cell-based HTS is being carried out on cultured cells propagated in two-dimensions (2D) on plastic surfaces optimized for tissue culture. At the same time, compelling evidence suggests that cells cultured in these non-physiological conditions are not representative of cells residing in the complex microenvironment of a tissue. This discrepancy is thought to be a significant contributor to the high failure rate in drug discovery, where only a low percentage of drugs investigated ever make it through the gamut of testing and approval to the market. Thus, three-dimensional (3D) cell culture technologies that more closely resemble <i>in vivo</i> cell environments are now being pursued with intensity as they are expected to accommodate better precision in drug discovery. Here we will review common approaches to 3D culture, discuss the significance of 3D cultures in drug resistance and drug repositioning and address some of the challenges of applying 3D cell cultures to high-throughput drug discovery.

Keywords

Drug discoveryDrugDrug developmentHigh-throughput screeningComputational biologyIdentification (biology)In vivoDrug repositioningCell culturePharmacologyComputer scienceMedicineBioinformaticsBiologyBiotechnologyGenetics

Affiliated Institutions

Related Publications

Publication Info

Year
2018
Type
review
Volume
9
Pages
6-6
Citations
1449
Access
Closed

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1449
OpenAlex
34
Influential
1286
CrossRef

Cite This

Sigrid A. Langhans (2018). Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning. Frontiers in Pharmacology , 9 , 6-6. https://doi.org/10.3389/fphar.2018.00006

Identifiers

DOI
10.3389/fphar.2018.00006
PMID
29410625
PMCID
PMC5787088

Data Quality

Data completeness: 86%